DJ Form 8.3 - The Vanguard Group, Inc.: Takeda Pharmaceutical Company Limited
Dow Jones received a payment from EQS/DGAP to publish this press release.
The Vanguard Group, Inc. ( )
Form 8.3 - The Vanguard Group, Inc.: Takeda Pharmaceutical Company Limited
26-Oct-2018 / 15:05 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the 'Code')
1. KEY INFORMATION
+-----------------------------+--------------------------------+
|(a) Full name of discloser: |The Vanguard Group, Inc. |
+-----------------------------+--------------------------------+
|(b) Owner or controller of | |
|interests and short positions| |
|disclosed, if different from | |
|1(a): | |
| | |
| | |
| | |
|The naming of nominee or | |
|vehicle companies is | |
|insufficient. For a trust, | |
|the trustee(s), settlor and | |
|beneficiaries must be named. | |
+-----------------------------+--------------------------------+
|(c) Name of offeror/offeree |Takeda Pharmaceutical Company |
|in relation to whose relevant|Limited |
|securities this form relates:| |
| | |
| | |
| | |
|Use a separate form for each | |
|offeror/offeree | |
+-----------------------------+--------------------------------+
|(d) If an exempt fund manager| |
|connected with an | |
|offeror/offeree, state this | |
|and specify identity of | |
|offeror/offeree: | |
+-----------------------------+--------------------------------+
|(e) Date position |25 October 2018 |
|held/dealing undertaken: | |
| | |
| | |
| | |
|For an opening position | |
|disclosure, state the latest | |
|practicable date prior to the| |
|disclosure | |
+-----------------------------+--------------------------------+
|(f) In addition to the |Yes, Shire plc |
|company in 1(c) above, is the| |
|discloser making disclosures | |
|in respect of any other party| |
|to the offer? | |
| | |
| | |
| | |
|If it is a cash offer or | |
|possible cash offer, state | |
|'N/A' | |
+-----------------------------+--------------------------------+
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one
class of relevant securities of the offeror or offeree named in 1(c), copy
table 2(a) or (b) (as appropriate) for each additional class of relevant
security.
(a) Interests and short positions in the relevant securities of the offeror
or offeree to which the disclosure relates following the dealing (if any)
+----------+------------+----------+-------------+-------------+
|Class of | ISIN: JP3463000004 |
|relevant | |
|security: | |
| | |
| | |
| | |
| | |
+----------+------------+----------+-------------+-------------+
| | Interests | Short positions |
| | | |
| | | |
| | | |
| | | |
+----------+------------+----------+-------------+-------------+
| | Number | % | Number | % |
+----------+------------+----------+-------------+-------------+
|(1) |31,098,133* | 3.97% | | |
|Relevant | | | | |
|securities| | | | |
|owned | | | | |
|and/or | | | | |
|controlled| | | | |
|: | | | | |
+----------+------------+----------+-------------+-------------+
|(2) | | | | |
|Cash-settl| | | | |
|ed | | | | |
|derivative| | | | |
|s: | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
+----------+------------+----------+-------------+-------------+
|(3) | | | | |
|Stock-sett| | | | |
|led | | | | |
|derivative| | | | |
|s | | | | |
|(including| | | | |
|options) | | | | |
|and | | | | |
|agreements| | | | |
|to | | | | |
|purchase/s| | | | |
|ell: | | | | |
+----------+------------+----------+-------------+-------------+
| |31,098,133* | 3.97% | | |
| | | | | |
| | | | | |
| | | | | |
|TOTAL: | | | | |
+----------+------------+----------+-------------+-------------+
*Please note that The Vanguard Group, Inc. does not have investment
discretion over 10,108,285 of these shares.
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other
employee options)
+------------------------------------------------------------+-+
|Class of relevant security in relation to which subscription| |
|right exists: | |
+------------------------------------------------------------+-+
|Details, including nature of the rights concerned and | |
|relevant percentages: | |
+------------------------------------------------------------+-+
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d)
(as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
+----------------+-------------+---------------+---------------+
| Class of |Purchase/sale| Number of |Price per unit |
| relevant | | securities | |
| security | | | |
| | | | |
| | | | |
+----------------+-------------+---------------+---------------+
|Common Stock |Sale |2,380 |4,383.30 JPY |
+----------------+-------------+---------------+---------------+
|Common Stock |Purchase |100 |4,528.00 JPY |
(MORE TO FOLLOW) Dow Jones Newswires
October 26, 2018 10:07 ET (14:07 GMT)
+----------------+-------------+---------------+---------------+
(b) Cash-settled derivative transactions
+-----------+-------------+-----------+------------+-----------+
| Class of | Product | Nature of | Number of | Price per |
| relevant | description | dealing | reference | unit |
| security | | | securities | |
| | | | | |
| | | | | |
| | e.g. CFD | e.g. | | |
| | |opening/clo| | |
| | | sing a | | |
| | |long/short | | |
| | | position, | | |
| | |increasing/| | |
| | |reducing a | | |
| | |long/short | | |
| | | position | | |
+-----------+-------------+-----------+------------+-----------+
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
+-----------+-------------+-----------+------------+-----------+
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
+------+--------+-------+-------+---------+----+-------+-------+
|Class |Product |Writing|Number |Exercise |Type|Expiry |Option |
| of |descript| , | of |price per| | date | money |
|releva|ion e.g.|purchas|securit| unit | | | paid/ |
| nt | call | ing, |ies to | | | |receive|
|securi| option |selling| which | |e.g.| | d per |
| ty | | , |option | |Amer| | unit |
| | |varying|relates| |ican| | |
| | | etc. | | | , | | |
| | | | | |Euro| | |
| | | | | |pean| | |
| | | | | |etc.| | |
+------+--------+-------+-------+---------+----+-------+-------+
| | | | | | | | |
+------+--------+-------+-------+---------+----+-------+-------+
(ii) Exercise
+----------+-----------+--------------+-----------+------------+
| Class of | Product | Exercising/ | Number of | Exercise |
| relevant |description| exercised |securities | price per |
| security | | against | | unit |
| | | | | |
| | | | | |
| | e.g. call | | | |
| | option | | | |
+----------+-----------+--------------+-----------+------------+
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
+----------+-----------+--------------+-----------+------------+
(d) Other dealings (including subscribing for new securities)
+-----------------+-----------------+--------+-----------------+
|Class of relevant|Nature of dealing|Details | Price per unit |
| security | | | (if applicable) |
| | | | |
| | | | |
| | e.g. | | |
| | subscription, | | |
| | conversion | | |
+-----------------+-----------------+--------+-----------------+
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
+-----------------+-----------------+--------+-----------------+
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
+--------------------------------------------------------------+
|Details of any indemnity or option arrangement, or any |
|agreement or understanding, formal or informal, relating to |
|relevant securities which may be an inducement to deal or |
|refrain from dealing entered into by the person making the |
|disclosure and any party to the offer or any person acting in |
|concert with a party to the offer: |
| |
| |
| |
|Irrevocable commitments and letters of intent should not be |
|included. If there are no such agreements, arrangements or |
|understandings, state 'none' |
+--------------------------------------------------------------+
| |
| |
| |
| |
| |
| |
| |
| |
| |
+--------------------------------------------------------------+
(b) Agreements, arrangements or understandings relating to options or
derivatives
+--------------------------------------------------------------+
|Details of any agreement, arrangement or understanding, formal|
|or informal, between the person making the disclosure and any |
|other person relating to: |
| |
| |
| |
|(i) the voting rights of any relevant securities under any |
|option; or |
| |
| |
| |
|(ii) the voting rights or future acquisition or disposal of |
|any relevant securities to which any derivative is referenced:|
| |
| |
| |
|If there are no such agreements, arrangements or |
|understandings, state 'none' |
+--------------------------------------------------------------+
| |
| |
| |
| |
| |
| |
| |
| |
| |
+--------------------------------------------------------------+
(c) Attachments
+----------------------------------------------------+---+
|Is a Supplemental Form 8 (Open Positions) attached? |NO |
+----------------------------------------------------+---+
+-------------------+-----------------+
| |26 October 2018 |
| | |
| | |
|Date of disclosure:| |
+-------------------+-----------------+
| |Shawn Acker |
| | |
| | |
|Contact name: | |
+-------------------+-----------------+
| |001-610-669-8989 |
| | |
| | |
|Telephone number: | |
+-------------------+-----------------+
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service and must also be emailed to the Takeover Panel at
monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is
available for consultation in relation to the Code's disclosure requirements
on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
[1].
Category Code: RET - Takeda Pharmaceutical Company Limited
TIDM:
LEI Code: 5493002789CX3L0CJP65
Sequence No.: 6344
EQS News ID: 738449
End of Announcement EQS News Service
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=d610e80acff92c902df9f1f3bdbd4b53&application_id=738449&site_id=vwd_london&application_name=news
(END) Dow Jones Newswires
October 26, 2018 10:07 ET (14:07 GMT)
